Comparative Pharmacology
Head-to-head clinical analysis: IMIPRAMINE HYDROCHLORIDE versus PERTOFRANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMIPRAMINE HYDROCHLORIDE versus PERTOFRANE.
IMIPRAMINE HYDROCHLORIDE vs PERTOFRANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at presynaptic neuronal membranes, increasing their synaptic concentrations. Also has anticholinergic, antihistaminergic, and alpha-1 adrenergic blocking effects.
Tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft.
Initial 75 mg/day orally in divided doses, increase to 150-200 mg/day; maximum 300 mg/day. For maintenance, 50-150 mg/day orally.
150-300 mg oral in divided doses per day; 75-150 mg IM in divided doses per day
None Documented
None Documented
Terminal half-life 11-25 hours (mean ~20 h); clinical context: steady-state achieved in ~1 week, dosing adjustment needed in hepatic impairment
Terminal elimination half-life is 14–21 hours. Steady-state is reached within 5–7 days. The half-life is prolonged in elderly and patients with hepatic impairment.
Renal (70% as metabolites, <5% unchanged), biliary/fecal (30%)
Primarily renal (70%), with 30% as unchanged drug; remainder as glucuronide and sulfate conjugates. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant